What else can obese patients do if they can't lose weight through diet, exercise, medication and surgery? Zuo Yuxing has been a gastroenterologist for seven years. Every time he meets such a patient in the clinic, he feels deeply confused and helpless.
Can obese patients only accept these ways? Are there other forms of treatment? Since then, these problems have been plaguing Zuo Yuxing. After moving to the medical equipment track, an expert meeting gave him the idea of treating obesity through the gastric bypass stent system, and he began to explore for a long time.
At the end of 2016, Zuo Yuxing founded Tangji Medical and devoted himself to the research and development of gastric bypass stent system. He hopes that with the help of this product, which is based on the principle of gastric bypass surgery and implanted through gastroscopy, patients with metabolic diseases such as obesity can regain a healthy life in a safer and more effective way.
Can weight loss therapy be more effective and safer?
From 1995 to 2002, Zuo Yuxing was also a gastroenterologist. At that time, the treatment of obesity in the domestic medical environment was still single, and most doctors only advised patients to lose weight through diet control and exercise, or to give symptomatic drugs for complications such as hypertension and hyperlipidemia. However, for many obese patients, the weight loss effect of these methods is still limited.
In 2002, Zuo Yuxing turned to the track of medical devices, hoping to find new solutions for obese patients through technological innovation. At the same time, weight loss surgery, represented by gastric bypass surgery, rose in China, and was later included in the guidelines, with strict restrictions on surgical indications and contraindications.
However, weight loss surgery is invasive and changes the normal physiological structure of the human body, which makes some obese patients feel conflicted. A gastric bypass operation usually takes 1.5-2 hours, while obese patients are overweight and some of them have complications such as cardiovascular and cerebrovascular diseases, which undoubtedly increases the risk of anesthesia.
Inspired by laparoscopic weight loss surgery, Zuo Yuxing began to think about whether a more effective and safer weight loss therapy could be developed based on the same principle?
In an exchange with American experts, Zuo Yuxing was inspired. He learned that gastric bypass surgery achieves weight loss by changing the process of digestion and absorption of food in the small intestine, which provided him with a new idea. He pondered whether a more minimally invasive approach could achieve a similar therapeutic effect to gastric bypass surgery?
With the keen insight of the doctor's profession and years of clinical experience, Zuo Yuxing put forward a bold idea: to put a membrane tube in the position of the duodenojejunal flexure to simulate the effect of gastric bypass surgery. The idea has been endorsed by experts in the United States, who agree that if this technology can be successfully implemented, it will have a revolutionary impact on the field of obesity treatment.
Many difficult problems need to be solved. He is still giving himself "examination questions"
Putting in the membrane tube is only an idea, and there are still many product details to be solved. To this day, interventional treatment of obesity is a new field, and many problems lack clinical data reference. At that time, Zuo Yuxing managed the sales work in more than ten provinces, and he could only use the short time from after work to before going to bed to think and deduce.
Recalling this period of time, Zuo Yuxing said that he seemed to have returned to his student days, practicing basic operations such as knotting and suturing repeatedly in the teaching and research room. Although it is unavoidable to feel monotonous and tired, every time he solves a difficult problem, he can go further to the product landing, and when he is tired, he often feels encouraged.
The first problem Zuo Yuxing encountered troubled him for a long time. In order to confirm the size of the membrane tube, we first need to know how long the human intestine is in its natural state. When he opened Surgery and Physiology, the result was 5-7 meters, but 5-7 meters was the length of the human intestinal tract, which would peristalsis, shrink and become shorter in the natural state. Zuo Yuxing consulted the surgeon again, but he found that the patient had to take anesthetics and muscle relaxants during the operation, and the measured length was still inaccurate. After consulting a large number of literature cross-validation, Zuo Yuxing concluded that the human intestinal tract should be 3-4 meters in the natural state.
Continuous peristalsis of the digestive tract in the natural state also brings another problem-how to ensure that the stent does not shift in the digestive tract and maintain the same frequency of peristalsis as the digestive tract? In addition, Zuo Yuxing has seen in many years of clinical practice that there are very few doctors who can operate enteroscopy. In order to benefit more obese patients with gastric bypass stents, it is necessary to enable them to be placed through gastroscopy.
Zuo Yuxing also hopes that obese patients will not have to carry stents for life, and that they will be removed after a period of time to see the obvious effect of weight loss, so as to reduce the impact on the normal physiological structure of the human body. In the process of thinking, Zuo Yuxing always imagines himself as an obese patient who is about to receive stent implantation, and constantly gives himself "test questions". He believes that obese patients already suffer many health risks and should not suffer new risks and pain from weight loss treatment.
However, this undoubtedly puts forward higher requirements for the structure, material and other details of the bracket.
A small membrane tube, how to subvert weight loss therapy?
After more than two years of intensive research and testing, the first sample of gastric bypass stent system was successfully trial-produced. At the end of 2016, Zuo Yuxing formally founded Tangji Medical, and devoted himself to the research and development of gastric bypass stent system and clinical application.
When the company started, there were only five people, but there were many technical problems to be solved. The duodenojejunal flexure connects the stomach to the intestinal tract. All food residues that are not fully digested in the stomach pass through here. Placing a stent may cause food adhesion and secondary infection. At the same time, bile, pancreatic juice and other digestive juices flow through here, and the stent must be able to withstand corrosion. How to make stents resistant to both infection and corrosion?
At first, Zuo Yuxing thought of covering the stent with a film to isolate food residues and digestive juices. However, after the experiment, it was found that this would lead to an increase in the weight of the stent, which could not peristalsis at the same frequency as the intestinal tract, and then lead to bacterial growth. Then we can only start with the stent material. Zuo Yuxing and his team did thousands of tests before they finally selected two suitable materials.
After five years of continuous product improvement, in 2017, the gastric bypass stent system entered the stage of animal experiments. After comparing monkeys, rabbits, dogs and other animals, they chose pigs with the closest digestive tract structure to the human body for the experiment. In two years, Zuo Yuxing and his team implanted gastric bypass stent systems into more than 200 experimental pigs. The analysis found that there was a significant difference in weight gain between the experimental group and the control group, with almost no weight gain in the stent-implanted pigs, while the average weight gain in the non-implanted pigs ranged from 100 to 300 grams per day.
In early 2019, in Beijing Friendship Hospital affiliated to Capital Medical University, the gastric bypass stent system entered the small sample human trial for the first time, and the first subject was Zuo Yuxing himself. Three months later, the stent was removed smoothly, and Zuo Yuxing's hanging heart was finally put down. With the news of success, he mentioned the human trial to his family for the first time. Before that, Zuo Yuxing had not told them that he had decided to be the first implanter of the product because he was afraid of his family's worries. Through the examination images after implantation, Zuo Yuxing was also pleased to see that the human intestinal tract is 3-4 meters in the natural state, which is almost the same as his own inference.
Later, when introducing the gastric bypass stent system to doctors, Zuo Yuxing would also use the results of this experiment to dispel their worries.
At the beginning of 2020, the outbreak of COVID-19 brought the whole country into silence, but Zuo Yuxing was excited about another thing-the results of the latest batch of human trials were announced. All patients lost a lot of weight, their blood sugar returned to normal, their physical condition was good, and there was no case of stent displacement. In August 2020, the gastric bypass stent system was specially approved by the State Drug Administration for innovative medical devices. At the beginning of 2021, Tangji Medical formally cooperated with seven third-class hospitals in China to carry out clinical trials of gastric bypass stent system registration, and more than 30 hospitals joined in.
On January 17 this year, the gastric bypass stent system was approved by the State Drug Administration as an innovative third-class medical device for obese patients with ineffective lifestyle adjustment, non-invasive treatment and poor drug treatment effect, thus becoming the first innovative third-class medical device for intestinal interventional treatment of obesity in the world.
Zuo Yuxing introduced that the gastric bypass stent system has been licensed for production and is entering the provincial procurement platform, which has been officially used in clinical practice on April 15 to provide a new treatment option for obese patients.
Turn on metabolic disease, New Era of Interventional Therapy
At the Second China Obesity Conference in 2023, Zuo Yuxing was invited to introduce the gastric bypass stent system. He emphasized that, unlike traditional obesity interventions such as "eating less", the gastric bypass stent system achieves weight loss and changes human metabolism through "less absorption", which means that it is also expected to be used in the treatment of other metabolic diseases.
As early as 2019, Tangji Medical and the First Affiliated Hospital of Medical College of Zhejiang University jointly carried out a clinical study on the use of gastric bypass stent system in obese non-alcoholic fatty liver disease. After three months of implantation treatment, all patients showed healthy weight loss. In addition, hepatic steatosis, liver enzymes, insulin resistance and metabolic parameters of patients were also improved, which also provided a strong support for the application of gastric bypass stent system in metabolic diseases such as fatty liver and diabetes.
Zuo Yuxing said that Tangji Medical may be the only company in China dedicated to the treatment of metabolic diseases through gastrointestinal intervention. He told the "medical think tank" that Tangji Medical has carried out clinical trials of diabetes indications in China. At the same time, a clinical trial of gastric bypass stent system for the treatment of obesity complicated with non-alcoholic steatohepatitis (NASH) has been carried out in China, and a small sample validation trial has been launched in Europe.
In the future, Tangji Medical will explore more possibilities of gastric bypass stent system in clinical application, increase investment in research and development and innovation, bring more new treatment options for patients with metabolic diseases such as obesity and diabetes, and open a new era of interventional treatment of metabolic diseases.